Literature DB >> 25980599

Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.

Laura B Monico1, Shannon Gwin Mitchell2, Jan Gryczynski3, Robert P Schwartz4, Kevin E O'Grady5, Yngvild K Olsen6, Jerome H Jaffe7.   

Abstract

Buprenorphine availability continues to expand as an effective treatment for opioid dependence, but increases in availability have also been accompanied by increases in non-prescribed use of the medication. Utilizing data from a randomized clinical trial, this mixed-method study examines associations between use of non-prescribed buprenorphine and subsequent treatment entry and retention. Quantitative analyses (N = 300 African American buprenorphine patients) found that patients with prior use of non-prescribed buprenorphine had significantly higher odds of remaining in treatment through 6 months than patients who were naïve to the medication upon treatment entry. Qualitative data, collected from a subsample of participants (n = 20), identified three thematic explanations for this phenomenon: 1) perceived effectiveness of the medication; 2) cost of obtaining prescription buprenorphine compared to purchasing non-prescribed medication; and 3) convenience of obtaining the medication via daily-dosing or by prescription compared to non-prescribed buprenorphine. These findings suggest a dynamic relationship between non-prescribed buprenorphine use and treatment that indicates potential directions for future research into positive and negative consequences of buprenorphine diversion.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Buprenorphine diversion; Opioid dependence; Treatment retention

Mesh:

Substances:

Year:  2015        PMID: 25980599      PMCID: PMC4561018          DOI: 10.1016/j.jsat.2015.04.010

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  40 in total

1.  Behavioral economics (Editorial).

Authors:  W K Bickel; L Green; R E Vuchinich
Journal:  J Exp Anal Behav       Date:  1995-11       Impact factor: 2.468

2.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

3.  Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence.

Authors:  Andrew A Monte; Todd Mandell; Bonnie B Wilford; Joseph Tennyson; Edward W Boyer
Journal:  J Addict Dis       Date:  2009-07

4.  Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers.

Authors:  Zev Schuman-Olivier; Mark Albanese; Sarah E Nelson; Lolita Roland; Francyne Puopolo; Lauren Klinker; Howard J Shaffer
Journal:  J Subst Abuse Treat       Date:  2010-07

5.  Factors associated with complicated buprenorphine inductions.

Authors:  Susan D Whitley; Nancy L Sohler; Hillary V Kunins; Angela Giovanniello; Xuan Li; Galit Sacajiu; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2010-07

6.  Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

Authors:  Raminta Daniulaityte; Russel Falck; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2011-10-28       Impact factor: 4.492

Review 7.  Quantifying reinforcement value and demand for psychoactive substances in humans.

Authors:  Adrienne J Heinz; Todd C Lilje; Jon D Kassel; Harriet de Wit
Journal:  Curr Drug Abuse Rev       Date:  2012-12

8.  Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Kevin E O'Grady; Robert P Schwartz
Journal:  Am J Addict       Date:  2009 Sep-Oct

9.  Cutaneous complications among i.v. buprenorphine users.

Authors:  Roger C M Ho; Emily C L Ho; Anselm Mak
Journal:  J Dermatol       Date:  2009-01       Impact factor: 4.005

10.  Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes.

Authors:  Chinazo O Cunningham; Robert J Roose; Joanna L Starrels; Angela Giovanniello; Nancy L Sohler
Journal:  J Addict Med       Date:  2013 Jul-Aug       Impact factor: 3.702

View more
  10 in total

1.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

2.  Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Authors:  Molly Doernberg; Noa Krawczyk; Deborah Agus; Michael Fingerhood
Journal:  Subst Abus       Date:  2019-04-22       Impact factor: 3.716

3.  Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.

Authors:  Raminta Daniulaityte; Ramzi W Nahhas; Sydney Silverstein; Silvia Martins; Angela Zaragoza; Avery Moeller; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2019-09-22       Impact factor: 4.492

4.  Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.

Authors:  David Hui; Zoe M Weinstein; Debbie M Cheng; Emily Quinn; Hyunjoong Kim; Colleen Labelle; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2017-05-16

5.  Emergency department patients with untreated opioid use disorder: A comparison of those seeking versus not seeking referral to substance use treatment.

Authors:  Edouard Coupet; Gail D'Onofrio; Marek Chawarski; E J Edelman; Patrick G O'Connor; Patricia Owens; Shara Martel; David A Fiellin; Ethan Cowan; Lynne Richardson; Kristen Huntley; Lauren K Whiteside; Michael S Lyons; Richard E Rothman; Michael Pantalon; Kathryn Hawk
Journal:  Drug Alcohol Depend       Date:  2020-11-26       Impact factor: 4.492

6.  Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.

Authors:  Arthur Robin Williams; Christine M Mauro; Tianshu Feng; Amanda Wilson; Angelo Cruz; Mark Olfson; Stephen Crystal; Hillary Samples; Lisa Chiodo
Journal:  J Subst Abuse Treat       Date:  2022-03-21

7.  Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply.

Authors:  Samantha G Auty; Michael D Stein; Alexander Y Walley; Mari-Lynn Drainoni
Journal:  J Subst Abuse Treat       Date:  2020-05-13

8.  Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?

Authors:  Robert G Carlson; Raminta Daniulaityte; Sydney M Silverstein; Ramzi W Nahhas; Silvia S Martins
Journal:  Int J Drug Policy       Date:  2020-04-17

9.  Retention of patients in opioid substitution treatment: A systematic review.

Authors:  Aisling Máire O'Connor; Gráinne Cousins; Louise Durand; Joe Barry; Fiona Boland
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

10.  Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.

Authors:  Marcus A Bachhuber; Cole Thompson; Ann Prybylowski; José Benitez; Silvana Mazzella; David Barclay
Journal:  Subst Abus       Date:  2018-05-04       Impact factor: 3.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.